NZ728962A - Compositions comprising amino acids for use in the treatment of stroke in patients with dysphagia - Google Patents
Compositions comprising amino acids for use in the treatment of stroke in patients with dysphagiaInfo
- Publication number
- NZ728962A NZ728962A NZ728962A NZ72896215A NZ728962A NZ 728962 A NZ728962 A NZ 728962A NZ 728962 A NZ728962 A NZ 728962A NZ 72896215 A NZ72896215 A NZ 72896215A NZ 728962 A NZ728962 A NZ 728962A
- Authority
- NZ
- New Zealand
- Prior art keywords
- dysphagia
- patients
- stroke
- treatment
- amino acids
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITTO20140806 | 2014-10-08 | ||
| PCT/IB2015/057662 WO2016055948A1 (en) | 2014-10-08 | 2015-10-07 | Compositions comprising amino acids for use in the treatment of stroke in patients with dysphagia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ728962A true NZ728962A (en) | 2019-05-31 |
Family
ID=52101507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ728962A NZ728962A (en) | 2014-10-08 | 2015-10-07 | Compositions comprising amino acids for use in the treatment of stroke in patients with dysphagia |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9707198B2 (enExample) |
| EP (1) | EP3006027B1 (enExample) |
| JP (1) | JP6447716B2 (enExample) |
| KR (1) | KR102077374B1 (enExample) |
| AU (1) | AU2015329581B2 (enExample) |
| CA (1) | CA2958033C (enExample) |
| DK (1) | DK3006027T3 (enExample) |
| ES (1) | ES2651903T3 (enExample) |
| HU (1) | HUE035699T2 (enExample) |
| NO (1) | NO3006027T3 (enExample) |
| NZ (1) | NZ728962A (enExample) |
| PL (1) | PL3006027T3 (enExample) |
| RU (1) | RU2668373C1 (enExample) |
| WO (1) | WO2016055948A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016181335A1 (en) * | 2015-05-14 | 2016-11-17 | Professional Dietetics S.P.A. | Compositions comprising amino acids for use in the treatment of mucositides in neoplasia patients undergoing radiation therapy and/or chemotherapy |
| IT201700087376A1 (it) * | 2017-07-28 | 2019-01-28 | Professional Dietetics Spa | Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4780475A (en) * | 1986-02-03 | 1988-10-25 | Cerra Frank B | Preparation for the prevention of catabolism |
| US5276018A (en) * | 1992-07-17 | 1994-01-04 | Brigham And Women's Hospital | Composition comprising amino acids and methods for decreasing muscle breakdown |
| IT1320783B1 (it) * | 2000-07-04 | 2003-12-10 | Professional Dietetics Srl | Composizioni a base di aminoacidi, atte al miglioramento delleprestazioni muscolari. |
| US20030060421A1 (en) * | 2001-07-19 | 2003-03-27 | Neuron Therapeutics, Inc. | Kits and compositions supporting intracranial perfusions |
| EP2275084A1 (en) * | 2009-07-15 | 2011-01-19 | Unilever PLC | Oral care composition |
| EP3231435A1 (en) * | 2009-07-20 | 2017-10-18 | Nestec S.A. | Methods of attenuating the loss of functional status |
| BR112013022060B1 (pt) * | 2011-03-01 | 2019-11-26 | Nestec Sa | produto nutricional, métodos para sua preparação e para melhorar sua coesão, e usos de um polímero de grau alimentício |
| JP2012214451A (ja) * | 2011-03-25 | 2012-11-08 | En Otsuka Pharmaceutical Co Ltd | 炎症性疾患用アミノ酸組成物 |
| JP5837315B2 (ja) * | 2011-03-25 | 2015-12-24 | イーエヌ大塚製薬株式会社 | 炎症性疾患用栄養組成物 |
| WO2012133198A1 (ja) * | 2011-03-25 | 2012-10-04 | イーエヌ大塚製薬株式会社 | 炎症性疾患用栄養組成物 |
| AU2012245002A1 (en) * | 2011-04-21 | 2013-11-28 | Fit-Bioceuticals Limited | Weight loss composition |
| RU2526826C2 (ru) * | 2012-10-24 | 2014-08-27 | Николай Владимирович Соловьёв | Композиция для парентерального введения, способ получения и применение композиции |
-
2015
- 2015-10-01 NO NO15187946A patent/NO3006027T3/no unknown
- 2015-10-01 PL PL15187946T patent/PL3006027T3/pl unknown
- 2015-10-01 ES ES15187946.7T patent/ES2651903T3/es active Active
- 2015-10-01 HU HUE15187946A patent/HUE035699T2/en unknown
- 2015-10-01 EP EP15187946.7A patent/EP3006027B1/en active Active
- 2015-10-01 DK DK15187946.7T patent/DK3006027T3/en active
- 2015-10-07 JP JP2017511782A patent/JP6447716B2/ja not_active Expired - Fee Related
- 2015-10-07 RU RU2017112492A patent/RU2668373C1/ru active
- 2015-10-07 AU AU2015329581A patent/AU2015329581B2/en not_active Ceased
- 2015-10-07 NZ NZ728962A patent/NZ728962A/en not_active IP Right Cessation
- 2015-10-07 CA CA2958033A patent/CA2958033C/en active Active
- 2015-10-07 KR KR1020177009224A patent/KR102077374B1/ko not_active Expired - Fee Related
- 2015-10-07 WO PCT/IB2015/057662 patent/WO2016055948A1/en not_active Ceased
- 2015-10-08 US US14/878,100 patent/US9707198B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170057308A (ko) | 2017-05-24 |
| DK3006027T3 (en) | 2017-12-18 |
| US9707198B2 (en) | 2017-07-18 |
| CA2958033A1 (en) | 2016-04-14 |
| HUE035699T2 (en) | 2018-05-28 |
| ES2651903T3 (es) | 2018-01-30 |
| WO2016055948A1 (en) | 2016-04-14 |
| KR102077374B1 (ko) | 2020-02-13 |
| CA2958033C (en) | 2019-07-16 |
| JP2017530103A (ja) | 2017-10-12 |
| EP3006027B1 (en) | 2017-11-15 |
| NO3006027T3 (enExample) | 2018-04-14 |
| AU2015329581B2 (en) | 2019-02-07 |
| EP3006027A1 (en) | 2016-04-13 |
| AU2015329581A1 (en) | 2017-03-02 |
| US20160101078A1 (en) | 2016-04-14 |
| PL3006027T3 (pl) | 2018-02-28 |
| RU2668373C1 (ru) | 2018-09-28 |
| JP6447716B2 (ja) | 2019-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500190A1 (en) | Compositions comprising amino acids for use in the treatment of mitochondrial dysfuntion-related diseases | |
| CL2017000201A1 (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
| SG10201811454WA (en) | Materials and methods for controlling infections | |
| EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| CL2016003422A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| EA202191513A1 (ru) | Снижение вязкости фармацевтических составов | |
| CL2016003423A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| BR112016021034A8 (pt) | composição farmacêutica, uso da mesma e kit | |
| AR109799A1 (es) | Composición para el tratamiento del cabello | |
| EA201790655A1 (ru) | Новые активаторы растворимой гуанилатциклазы и их применение | |
| MX2022014634A (es) | Metodos para la administracion linfatica de agentes activos. | |
| CL2015002897A1 (es) | Inhibidores de bace1 | |
| PH12020500189A1 (en) | Compositions comprising amino acids for use in the treatment of mitochondrial dysfuntion-related diseases | |
| CL2020003209A1 (es) | Composición de aminoácidos para su uso en la prevención y tratamiento de enfermedades hepáticas | |
| MY187022A (en) | Compositions comprising amino acids for use in the treatment of mucositides in neoplasia patients undergoing radiation therapy and/or chemotherapy | |
| MX2017006748A (es) | Composiciones de aminoácidos para el tratamiento de síntomas de enfermedades. | |
| BR112019024667A2 (pt) | Uso de um agente bioativo, e, de uma composição | |
| MX2018006820A (es) | Complejos de aminoacidos metalicos para la acumulacion bacteriana. | |
| UY33663A (es) | Derivados amínicos para el tratamiento de trastornos proliferativos de la piel | |
| NZ728962A (en) | Compositions comprising amino acids for use in the treatment of stroke in patients with dysphagia | |
| MX2021009344A (es) | Composiciones con aminoacidos para el uso y tratamiento de lesiones del sistema nervioso central. | |
| MX2016009464A (es) | Composiciones para el uso en el tratamiento de afecciones alergicas. | |
| MX2021005807A (es) | Aminoacidos grasos n-acilados para reducir la variabilidad de absorcion en composiciones basadas en cannabinoides. | |
| EA202090480A1 (ru) | Композиция для контролируемой стимуляции яичников | |
| NZ734845A (en) | Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 OCT 2020 BY IPAN GMBH Effective date: 20190919 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 OCT 2021 BY IPAN GMBH Effective date: 20200929 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 OCT 2022 BY IPAN GMBH Effective date: 20210917 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 OCT 2023 BY IPAN GMBH Effective date: 20220916 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 OCT 2024 BY IPAN GMBH Effective date: 20230918 |
|
| LAPS | Patent lapsed |